Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005

Abstract

The increase in microorganisms that have developed resistance to currently available antimicrobial agents has become a major cause for concern worldwide. These organisms are widespread in hospitals but also occur increasingly in the community. Some of these strains are multiresistant and the agents available to treat infections caused by them are few and dwindling. Over recent years there have been a number of responses by national, international and professional bodies to this situation, many aimed at curbing this unprecedented growth in resistance, but there is an increasing recognition that a major problem in the management of infections caused by such organisms is the paucity of new drugs, vaccines and diagnostic aids. A conference, organized by the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) on behalf of the UK Department of Health and sponsored by the BSAC, was held in Birmingham in December 2005 with the aim of addressing these problems. Conference attendees included those from academia, industry, funding agencies, healthcare management, the European Medicines Agency (EMEA), the European Centre for Disease Prevention and Control (ECDC), European Directorates and representatives of EU governments. Following a number of keynote presentations which identified major issues, there were a series of workshops which addressed specific questions and produced a number of recommendations. These recommendations were discussed by all delegates. The lack of new anti-infectives and the reasons for this were discussed in some detail. Major pharmaceutical companies no longer find this area as financially rewarding as other therapeutic areas while smaller biotechnology companies, who are seen as more innovative, are hampered by a lack of funding. In spite of a few marked successes, the use of vaccines has had minimal impact in the field of bacterial infections, and progress in this field also suffers from a lack of funding. Diagnostics could aid in the better use of antibacterials but need greater acceptance in the healthcare system, which does not generally appreciate their cost-efficacy. The major recommendations were as follows: (i) Increased efforts are needed to reduce the spread of resistant strains both in the environment and in hospitals--these include improved hygiene and decreased use of some antimicrobials. (ii) Surveillance of resistance is a key factor and improved technology (e.g. IT systems) is needed to improve the potential for surveillance data to inform clinical practice. (iii) Rapid, sensitive and specific diagnostics are urgently needed and the issue of reimbursement needs to be addressed. (iv) More accurate estimates of the cost-efficacy of using anti-infectives and diagnostics are urgently needed. (v) Vaccine technology is available but is underused for the prevention of bacterial infections, particularly those caused by organisms resistant to antimicrobials. (vi) Incentives are required to encourage large pharmaceutical companies to partner small biotechnology companies, which a...

Prevalence, risk factors and multidrug resistance profile of Staphylococcus aureus isolated from bovine mastitis in selected dairy farms in and around Asella town, Arsi Zone, South Eastern Ethiopia

“…Antibiotic resistance seems to be increasing, and multiple antibiotic resistant strains have started to emerge (Otter and French, 2010). Infections with antibiotic resistant bacteria have been known to be associated with frequent treatment failure and increased severity of the disease (Finch and Hunter, 2006;Swartz, 2004;Angulo et al, 2004). One of the most important bacteria in this regard is S. aureus, in particular its methicillin-resistant strains (Cosgrove et al, 2003;von Eiffet al, 2001).…”

Translational Medicine Policy Issues in Infectious Disease

“…Th e nature of the current impediments to innovation for both large pharmaceutical and smaller biotechnology companies has been discussed extensively in the EASAC reports and elsewhere [for example, for antibiotics (3,22,23) and for vaccines (24)], and the need for innovative incentives to encourage antibacterial R&D has become a priority for the current presidency of the EU Council. Although there are many issues to face in encouraging innovation-for example, in the regulation of marketing, pricing, and reimbursement to counter industry perceptions of the declining return on investment in this area-some optimism that new approaches to risk-sharing in public-private partnership will help drive R&D is appropriate.…”

“…In England, for example, the direct economic burden calculated from the cost of primary care, hospital admission, and hospitalacquired infection was estimated as up to $15 billion annually (3). The net impact is much greater when other ramifications are included.…”

Biosensors in Antimicrobial Drug Discovery: Since Biology until Screening Platforms

“…The progress in biosensor development is a promising field of application in the antimicrobial research, as useful tool in the discovery of new antimicrobial compounds [8]. Also, biosensors can also be used to develop new diagnostic techniques more specific to detect the emergence of antimicrobial resistance in hospital environment and clinical samples [8][9][10][11]. As well as the analysis and detection of microbial food contaminants [12].…”